was a 55.6% reduction in mean percent change from baseline in inflammatory lesion counts in tazarotene-treated patients aged 10-13 years, compared with a 37.0% reduction in the vehicle arm (P<0.01; Figure 3). Among tazarotene-treated patients 14-17 years of age, mean percent inflammatory lesion count reduction was 53.3% compared with a 41.2% reduction with vehicle (P<0.001). At week 8, there was also a significant reduction in mean percent inflammatory lesion counts in the tazarotene 0.045% lotion group versus vehicle among patients 14-17 years of age (43.6% vs 34.6%, P=0.004; Figure 3). Mean percent reductions in noninflammatory lesion counts were significantly greater with tazarotene 0.045% than with vehicle in both age groups at weeks 4, 8, and 12 (P<0.05, all; Figure 4). Improvement in acne lesions are shown in Figure 5.
When comparing tazarotene-treated patients in both age groups, there were no statistically significant differences in lesion count reductions or percent of patients achieving treatment success at any timepoint.